Linear and micronodular neuroendocrine cell hyperplasia in an ovarian mucinous cystadenoma

Dainese, Emanuele; Cimetti, Laura; Capella, Carlo; Riva, Cristina

doi:10.1016/j.prp.2013.06.008

Cited by 3 publications

(2 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Positivity (51%-100%) "pseudohyperplasia" (37)(38)(39). The highest number of positive cases in our study was for INSM1 with 48% of mucinous tumors showing any degree of positivity, followed by chromogranin.…”

Section: Discussionmentioning

confidence: 60%

“…Moreover, in rare cases, NE cell micronests have been reported in ovarian mucinous tumors. Sometimes the NE cells can be present within the ovarian stroma after “atrophy” of the mucinous elements and mimic a NE tumor similar to atrophic type A gastritis; this phenomenon has been referred to as “pseudohyperplasia” 37–39 . The highest number of positive cases in our study was for INSM1 with 48% of mucinous tumors showing any degree of positivity, followed by chromogranin.…”

Section: Discussionmentioning

confidence: 67%

See 1 more Smart Citation

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Bártů

Němejcová

Michálková

et al. 2023

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

Expression of neuroendocrine (NE) markers in primary ovarian non-NE epithelial tumors has rarely been evaluated. The aim of our study was to evaluate the expression of the most widely used NE markers in these neoplasms and to determine any prognostic significance of NE marker expression. The cohort consisted of 551 primary ovarian tumors, including serous borderline tumors, low-grade serous carcinomas, high-grade serous carcinomas (HGSC), clear cell carcinomas, endometroid carcinomas, mucinous borderline tumors, and mucinous carcinomas. Immunohistochemical analysis was performed using antibodies against INSM1, synaptophysin, chromogranin, and CD56 on tissue microarray. Positivity for INSM1, synaptophysin, chromogranin, and CD56 was most frequently observed in mucinous tumors (48.7%, 26.0%, 41.5%, and 100%, respectively). The positivity for these NE markers was mostly restricted to nonmucinous elements distributed throughout the tumor. The mucinous borderline tumor and mucinous carcinomas groups had similar proportions of positivity (mucinous borderline tumor: 53%, mucinous carcinomas: 39%). In the other tumor types, except for HGSC, there was only focal expression (5%–10%) or negativity for NE markers. HGSC showed high CD56 expression (in 26% of cases). Survival analysis was only performed for CD56 in HGSC as this was the only group with sufficient positive cases, and it showed no prognostic significance. Except for mucinous tumors, expression of NE markers in non-NE ovarian epithelial tumors is low. CD56 expression in HGSC occurs frequently but is without diagnostic or prognostic value.

show abstract

Section: Discussionmentioning

confidence: 60%

Section: Discussionmentioning

confidence: 67%

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Bártů

Němejcová

Michálková

et al. 2023

International Journal of Gynecological Pathology

View full text Add to dashboard Cite

show abstract

Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma

et al. 2014

View full text Add to dashboard Cite

Neuroendocrine differentiation in high-grade serous ovarian carcinomas has only rarely been described. However, in our consultancy experience, we have been pointed at a case of neuroendocrine relapse in a patient with high-grade serous ovarian carcinoma where retrospectively, a minor neuroendocrine component in the primary tumor could be detected. Hypothesizing that immunohistochemical evidence of neuroendocrine differentiation might be more frequent in ovarian carcinoma than suspected by morphology, we immunophenotyped the tissue microarrays (TMAs) of a cohort of 178 high-grade serous carcinomas for chromogranin and synaptophysin expression. Synaptophysin expression was found in 12 (6.7 %) out of 172 patients, and chromogranin A expression was seen in 36 (20.7 %) out of 174 patients. Kaplan-Meier analysis revealed that carcinomas with synaptophysin expression of >20 % of positive cells (n = 4) had a significantly shorter survival time than those with 0-20 % of positive cells (p < 0.0001). Synaptophysin expression remained a significant prognostic factor in multivariate analysis (HR = 10.82, 95 % confidence interval 3.10-37.71, p < 0.0001), independently of age, FIGO stage, and residual tumor after surgery. A trend toward shorter survival was seen in patients with tumors that expressed chromogranin, irrespective of the amount of positive cells (p = 0.173). A neuroendocrine differentiation is important to keep in mind when a neuroendocrine tumor of unknown primary is detected in regional or temporal connection with an ovarian carcinoma. A minor neuroendocrine component in ovarian high-grade serous carcinomas might imply a dismal prognosis.

show abstract

Recombinant Antibodies as Reagents

Johnson¹

2015

MATER METHODS

View full text Add to dashboard Cite

Linear and micronodular neuroendocrine cell hyperplasia in an ovarian mucinous cystadenoma

Cited by 3 publications

References 14 publications

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Neuroendocrine Marker Expression in Primary Non-neuroendocrine Epithelial Tumors of the Ovary: A Study of 551 Cases

Prognostic impact of neuroendocrine differentiation in high-grade serous ovarian carcinoma

Recombinant Antibodies as Reagents

Contact Info

Product

Resources

About